Annual Survey Results:

Speaker Interviews:

Exclusive interview with:

Anne Kerber, Senior Vice President, Cell Therapy Development, Bristol Myers Squibb

interview screenshot

Past CAR-TCR Summit Presentations:

Barbara content front page screenshot

Next Generation Approaches for Allogeneic CAR T in Solid Tumor Indications

Barbra Sasu, Chief Scientific Officer, Allogene Therapeutics

Executing Complex Pipelines in the Autologous Cell Therapy Space-Focusing on Performance & Scale

Cedrik Britten, Chief Medical Officer, Immatics

cedrik content front page screenshot


CAR-TCR Summit - CFBM Whitepaper

Considerations to Get Your CAR-T Testing Strategy Right

Provided by Center for Breakthrough Medicines

Hanson Wade Intelligence Reports:

Tackling the Solid Tumor Space

Data provided by Beacon Targeted Therapies

beacon reprot front cover

Manufacturing Challenges & Considerations for Allogeneic Cell Therapy

Hanson Wade Intelligence

The allogeneic cell therapy space has many development and manufacturing bottlenecks which are further compounded by the diversity of cell types, delivery systems and gene editing technologies that are now being pursued in the clinic.

To better elucidate these challenges Hanson Wade Intelligence, our Market Research division, spoke to 15 key opinion leaders within the allogeneic cell therapy space. We summarised their views alongside quantitative insights from our Beacon Adoptive Cell database in this opinion review.

This report aims to provide cell therapy developers with valuable insights on the main allogeneic manufacturing challenges and considerations for optimisation of key stages of development.